Advances of anaplastic lymphoma kinase in non-small cell lung cancer

Abstract

Fang Shu, Pan Zhifeng. Advances of anaplastic lymphoma kinase in non-small cell lung cancer[J]. Journal of International Oncology, 2014, 41(8): 592-594.

［1］ Reck M, von Pawel J, Zatloukal P, et al. Phase Ⅲ trial of cisplatin plus gemcitabine with either placebo or bevacizumab as firstline therapy for nonsquamous nonsmallcell lung cancer: AVAil［J］. J Clin Oncol, 2009, 27(8): 1227-1234. ［2］ Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in nonHodgkin′s lymphoma［J］. Science, 1994, 263(5151): 1281-1284. ［3］ Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4ALK fusion gene in nonsmallcell lung cancer［J］. Nature, 2007, 448 (7153): 561-566. ［4］ Zhang S, Wang F, Keats J, et al. Crizotinibresistant mutants of EML4ALK identified through an accelerated mutagenesis screen［J］. Chem Biol Drug Des, 2011, 78 (6): 999-1005. ［5］ Weickhardt AJ, Aisner DL, Franklin WA, et al. Diagnostic assays for identification of anaplastic lymphoma kinasepositive nonsmall cell lung cancer［J］. Cancer, 2013, 119(8): 1467-1477. ［6］ MinoKenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALKrearranged lung adenocarcinomas by standard immunohistochemistry［J］. Clin Cancer Res, 2010, 16(5): 1561-1571. ［7］ Sun JM, Choi YL, Won JK, et al. A dramatic response to crizotinib in a nonsmallcell lung cancer patient with IHCpositive and FISHnegative ALK［J］. J Thorac Oncol, 2012, 7(12): e36-38. ［8］ Wallander ML, Geiersbach KB, Tripp SR, et al. Comparison of reverse transcriptionpolymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubuleassociated proteinlike 4anaplastic lymphoma kinase fusionpositive nonsmall cell lung carcinoma: implications for optimal clinical testing［J］. Arch Pathol Lab Med, 2012, 136(7): 796-803. ［9］ Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive nonsmallcell lung cancer: updated results from a phase 1 study［J］. Lancet Oncol, 2012, 13(10): 1011-1019. ［10］ Shaw AT, Yeap BY, MinoKenudson M, et al. Clinical features and outcome of patients with nonsmallcell lung cancer who harbor EML4ALK［J］. J Clin Oncol, 2009, 27(26): 4247-4253. ［11］ Rodig SJ, MinoKenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALKrearranged lung adenocarcinoma in the western population［J］. Clin Cancer Res, 2009, 15(16): 5216-5223. ［12］ Inamura K, Takeuchi K, Togashi Y, et al. EML4ALK fusion is linked to histological characteristics in a subset of lung cancers［J］. J Thorac Oncol, 2008, 3(1): 13-17. ［13］ Wong DW, Leung EL, So KK, et al. The EML4ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wildtype EGFR and KRAS［J］. Cancer, 2009, 115(8): 1723-1733. ［14］ Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression［J］. Mol Cancer, 2010, 9: 188. ［15］ Kris MG, Johnson BE, Kwiatkowski DJ, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI′s Lung Cancer Mutation Consortium (LCMC)［J］. Am Soc Clin Oncol, 2011, 29 Suppl: CRA7506. ［16］ Rosell R, Massuti Sureda B, Costa C, et al. Concomitant actionable mutations and overall survival (OS) in EGFRmutant nonsmallcell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4ALK(V3)［J］. Ann Oncol, 2012, 23 Supple 9: abstract LBA31. ［17］ Koh Y, Kim DW, Kim TM, et al. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinasepositive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors［J］. J Thorac Oncol, 2011, 6(5): 905-912. ［18］ Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALKrearranged adenocarcinoma［J］. Lung Cancer, 2012, 76(3): 403-409. ［19］ Blackhall F, Peters S, Kerr KM, et al. Prevalence and clinical outcomes for patients with ALK gene rearrangement in Europe: preliminary results from the European Thoracic Oncology Platform Lungscape Project［J］. Ann Oncol, 2012, 23 Supple 9: abstract 1670. ［20］ Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in nonsmallcell lung cancer［J］. N Engl J Med, 2010, 363(18): 1693-1703. ［21］ Kim DW, Ahn MJ, Shi Y, et al. Updated results of a global phase II study with crizotinib in advanced ALKpositive nonsmall cell lung cancer (NSCLC)［J］. Ann Oncol, 2012, 23 Supple 9: abstract 1230. ［22］ Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALKpositive lung cancer［J］. N Engl J Med, 2013, 368(25): 2385-2394. ［23］ Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALKpositive nonsmallcell lung cancer: updated results from a phase 1 study［J］. Lancet Oncol, 2012, 13(10): 1011-1019. ［24］ Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged nonsmall cell lung cancer［J］. Clin Cancer Res, 2012, 18(5): 1472-1482. ［25］ Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant［J］. Cancer Cell, 2011, 19(5): 679-690. ［26］ Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALKrearranged advanced nonsmallcell lung cancer (AF001JP study): a singlearm, openlabel, phase 12 study［J］. Lancet Oncol, 2013, 14(7): 590-598. ［27］ Shaw AT, Camidge DR, Felip E, et al. Results of firstinhuman phase I study of the ALK inhibitor LDK378 in advanced solid tumors［J］. Ann Oncol, 2012, 23 Supple 9: abstract 4400. ［28］ Gettinger S, Weiss GJ, Salgia R, et al. A firstinhuman dosefinding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies［J］. Ann Oncol, 2012, 23 Supple 9: abstract 4390.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Huang Hui, Ding Jianghua.Advances in targeting FGFR2 for treatment of advanced cholangiocarcinoma[J]. Journal of International Oncology, 2023, 50(9): 569-573.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[7]	Liu Bohan, Huang Junxing.Research progress of solute carriers related genes in malignant tumors[J]. Journal of International Oncology, 2023, 50(5): 280-284.
[8]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.Research progress on targeted therapy of breast cancer with low expression of HER2[J]. Journal of International Oncology, 2023, 50(4): 236-240.
[9]	Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757.
[10]	Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui.Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(12): 758-762.
[11]	Jiang Shan, Xu Ximing.Recent progresses of targeted therapy and immunotherapy of hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(11): 688-695.
[12]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing.Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy[J]. Journal of International Oncology, 2023, 50(10): 600-607.
[13]	Zhang Jingxian, Su Jianfei, Wei Xueqin, Yi Dan, Li Xiaojiang.Treatment status of non-small cell lung cancer with METexon14 skipping mutation[J]. Journal of International Oncology, 2023, 50(1): 37-41.
[14]	Song Jia, Hu Qinyong.Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma[J]. Journal of International Oncology, 2022, 49(9): 550-554.
[15]	Zhang Jingxian, Yi Dan, Li Xiaojiang.Application of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(5): 296-301.

Advances of anaplastic lymphoma kinase in non-small cell lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments